Explore Summary, Communication, and more!

Explore related topics

Summary of PD-L1 antibody and methods to determine PD-L1 'positiveness' in avelumab studies presented at ASCO2016 http://medi-paper.com/medical-communications/

Summary of antibody and methods to determine 'positiveness' in…

Summary slides on the most important ESMO16 Avelumab & Tremelimumab data. Maybe used as long as the source "MediPaper - http://Medi-Paper.com" is properly referenced. See for details and PPT download: http://medi-paper.com/esmo-2016-durvalumab/ #ESMO16 #Avelumab #tremelimumab #AstraZeneca #Pfizer #lungcancer #nsclc #skincancer #merkelcell #ovariancancer #bladdercancer #ESMO2016 #immunecheckpoint #immunotherapy #immunooncology #PD-L1 #PD1 #CTLA4

The 2016 ASCO Ovarian Cancer Guideline for Neo-adjuvant Chemotherapy was published in the Journal of Clinical Oncology. Read the highlights on MediPaper

Summary of PD-L1 antibody and methods to determine PD-L1 'positiveness' in durvalumab studies presented at ASCO2016 http://medi-paper.com/medical-communications/

Summary of antibody and methods to determine 'positiveness' in…

Summary of PD-L1 antibody and methods to determine PD-L1 'positiveness' in atezolizumab (Tecentriq) studies presented at ASCO2016 http://medi-paper.com/medical-communications/

Summary of antibody and methods to determine 'positiveness' in…

Summary of PD-L1 antibody and methods to determine PD-L1 'positiveness' in nivolumab (Opdivo) studies presented at ASCO2016 http://medi-paper.com/medical-communications/

Summary of antibody and methods to determine 'positiveness' in…

Summary of PD-L1 antibody and methods to determine PD-L1 'positiveness' in avelumab studies presented at ASCO2016 http://medi-paper.com/medical-communications/

biomarker for response. MediPaper has an overview of data.

List of #FDA #Approved #ImmuneCheckpoint #Inhibitors. Updated 10-May-2017 #Durvalumab #Imfinzi® #mUCC. Download the free #PPT https://medi-paper.com/approved-immunotherapies/

Hire a contemporary and professional medical writer today.

List of #FDA #Approved #ImmuneCheckpoint #Inhibitors. Updated 06-Feb-2017 #Nivolumab #mUCC. Download the free #PPT

List of #FDA #Approved #ImmuneCheckpoint #Inhibitors. Updated 06-Feb-2017 #Nivolumab #mUCC. Download the free #PPT

Summary slides on the most important Atezolizumab (Tecentriq™) ESMO 2016 data. Maybe used as long as the source "MediPaper - http://Medi-Paper.com" is properly referenced. See for details and PPT download: http://medi-paper.com/esmo-2016-atezolizumab/  #ESMO16 #Atezolizumab #Tecentriq #Genentech #Roche #lungcancer #skincancer #bladdercancer #ESMO2016 #ESMO #immunecheckpoint #immunotherapy #PDL1 #PD1 #immunooncology

The 2016 ASCO Ovarian Cancer Guideline for Neo-adjuvant Chemotherapy was published in the Journal of Clinical Oncology. Read the highlights on MediPaper

Summary of PD-L1 antibody and methods to determine PD-L1 'positiveness' in pembrolizumab (Keytruda) studies presented at ASCO2016 http://medi-paper.com/medical-communications/

Summary of antibody and methods to determine 'positiveness' in…

SABCS 2016: Extended Letrozole Therapy May Have Limited Benefits

SABCS 2016: Extended Letrozole Therapy May Have Limited Benefits

CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology  https://medi-paper.com/medical-communications/

CSA2017 中华医学会第25 次全国麻醉学术年会 2017 郑州 25th Annual Meeting of the Chinese Society of Anaesthesiology https://medi-paper.com/medical-communications/

Summary slides on the most important Pembrolizumab (Keytruda™) ESMO 2016 data. Maybe used as long as the source "MediPaper - Medi-Paper.com" is properly referenced. See for details and PPT download: http://medi-paper.com/esmo-2016-pembrolizumab/

Summary slides on the most important Pembrolizumab (Keytruda™) ESMO 2016 data. Maybe used as long as the source "MediPaper - Medi-Paper.com" is properly referenced. See for details and PPT download: http://medi-paper.com/esmo-2016-pembrolizumab/

Approved Immunotherapies

Overview of US FDA approved immune checkpoint inhibitors.

Summary slides on the most important Ribociclib and Abemaciclib data. Maybe used as long as the source "MediPaper - Medi-Paper.com"; is properly referenced. See for details and PPT download: http://medi-paper.com/asco-2016-ribociclib/   #ASCO16 #palbociclib #Ibrance #Pfizer #ribociclib #Lee011 #abemaciclib #Lilly #Novartis #breastcancer #ovariancancer #ASCO2016 #cdk46 #hormone-resistant #luminal #post-menopausal #pre-menopausal #peri-menopausal #lee011 #LY2835219 #novartis #eli lilly

Summary slides on the most important Ribociclib and Abemaciclib data. Maybe used as long as the source "MediPaper - Medi-Paper.com"; is properly referenced. See for details and PPT download: http://medi-paper.com/asco-2016-ribociclib/ #ASCO16 #palbociclib #Ibrance #Pfizer #ribociclib #Lee011 #abemaciclib #Lilly #Novartis #breastcancer #ovariancancer #ASCO2016 #cdk46 #hormone-resistant #luminal #post-menopausal #pre-menopausal #peri-menopausal #lee011 #LY2835219 #novartis #eli lilly

Pinterest
Search